Hypofractionated Radiation Therapy for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Hypofractionated Radiation Therapy for Breast Cancer?
Research shows that hypofractionated radiation therapy (HFRT) is as effective and safe as traditional radiation therapy for early breast cancer, with fewer treatment sessions needed. Studies also indicate its growing use in real-world settings and its potential benefits for patients and healthcare facilities.12345
Is hypofractionated radiation therapy safe for humans?
Research shows that hypofractionated radiation therapy (HFRT) is generally safe for treating breast cancer, with similar safety levels to traditional radiation therapy. Studies have looked at side effects and found that HFRT is well-tolerated, although concerns about local control and toxicity still exist.12456
How is hypofractionated radiation therapy different from other treatments for breast cancer?
Hypofractionated radiation therapy (HFRT) is unique because it delivers higher doses of radiation over fewer sessions compared to conventional radiotherapy, making the treatment period shorter. This approach is becoming a standard for breast cancer, especially after breast-conserving surgery, and is associated with similar effectiveness and safety as traditional methods.12367
What is the purpose of this trial?
The primary objective of this study is to document lymphedema rates in patients requiring regional nodal irradiation (RNI) who receive hypofractionated radiation as compared to conventional radiation.
Research Team
Shane Stecklein, MD, PhD
Principal Investigator
University of Kansas Medical Center
Eligibility Criteria
This trial is for women with certain stages of breast cancer who may be of child-bearing age and agree to use contraception. They should have had prior surgery or chemotherapy but no radiation in the target area, and their physical condition must allow them to participate actively in daily life.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive hypofractionated radiation therapy daily for 4 weeks
Follow-up
Participants are monitored for lymphedema rates, cosmetic outcomes, local recurrence, quality of life, and range of motion
Treatment Details
Interventions
- Hypofractionated Radiation Therapy
Hypofractionated Radiation Therapy is already approved in United States, European Union, Canada for the following indications:
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Kansas Medical Center
Lead Sponsor